TiGenix initiates Phase III trial of Cx601 to treat perianal fistulas

Belgium-based biopharmaceutical firm TiGenix has marked the initiation of a Phase III clinical trial of Cx601 for the treatment of complex perianal fistulas in Crohn's disease patients with its first European investigator meeting.
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news